Skip to main content
Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA — Investor Relations & Filings

Ticker · HYL ISIN · BE0974363955 LEI · 875500LZIWS7QEQE0I73 BR Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2026-05-08 Audit Report / Informat…
Country BE Belgium
Listing BR HYL

About Hyloris Pharmaceuticals SA

https://hyloris.com/

Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's strategy centers on reformulating and repurposing established drugs to create value-added medicines for patients, healthcare professionals, and payors. By utilizing established regulatory pathways, such as the FDA's 505(b)(2) process, Hyloris aims to reduce development timelines, costs, and risks. The company has built a broad, patented portfolio of product candidates. Its commercialized products include Sotalol IV for the treatment of atrial fibrillation and Maxigesic® IV, a non-opioid for post-operative pain. In addition to its core focus, Hyloris also develops and commercializes high-barrier generic products.

Recent filings

Filing Released Lang Actions
10_Hyloris Pharma STAT_ PIE - BE Rapport comptes statutaires FR_SIGNED_300426.pdf
Audit Report / Information Classification · 100% confidence The document is a detailed auditor's report (Rapport du commissaire) addressed to the general assembly for the fiscal year ending December 31, 2025. It includes the auditor's opinion on the annual financial statements, audit scope, key audit matters, responsibilities of management and auditor, and compliance with legal and regulatory requirements. The presence of detailed audit procedures, financial figures, and the auditor's opinion on the annual accounts clearly identifies this as an Audit Report. It is not the full Annual Report (10-K) since it focuses on the auditor's findings and opinion rather than the company's full financial and operational disclosures. The document is also not a brief announcement or certification but a substantive audit report. Therefore, the correct classification is Audit Report / Information (AR). FY 2025
2026-05-08 French
8_2025 12 31 - Hyloris Pharmaceuticals - Rapport de Gestion FR - Signé.pdf
Annual Report Classification · 100% confidence The document is titled 'RAPPORT ANNUEL DU CONSEIL D'ADMINISTRATION POUR L'EXERCICE SOCIAL SE CLÔTURANT LE 31 DÉCEMBRE 2025' which translates to 'Annual Report of the Board of Directors for the fiscal year ending December 31, 2025'. It contains detailed financial data including revenues, expenses, balance sheet items, financial results, and risk factors for the full fiscal year 2025. The length is substantial (15,000 characters) and the content is comprehensive, covering the company's financial performance and management commentary for the year. This matches the definition of an Annual Report (10-K) which is an official yearly report covering company activity and full financial performance. There is no indication that this is merely an announcement or a certification, and it is not a quarterly or interim report. Therefore, the correct classification is Annual Report (10-K). FY 2025
2026-05-08 French
6_Remuneration Policy 2026_Hyloris Pharmaceuticals_Update for GA 2026_translated FR_20260508.pdf
Remuneration Information Classification · 95% confidence The document is titled 'Remuneration Policy 2026 - 2029' and extensively discusses the remuneration policy for the board of directors, executive committee members, and other senior management. It references the approval by the Board of Directors and the General Assembly of Shareholders, and details principles, objectives, and changes in remuneration policy. The content is focused on compensation structures, governance around pay, and related procedures. This matches the definition of a Remuneration Information report, which details compensation for top executives and directors. The document is substantive and not merely an announcement or a brief summary, and it is not a proxy solicitation or governance structure report. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2026-05-08 French
Hyloris_Communique Presse_Convocation Assemblee Generale_FR_20260508.pdf
AGM Information Classification · 95% confidence The document is a press release announcing the date and details of the Annual General Meeting (AGM) of Hyloris Pharmaceuticals scheduled for June 9, 2026. It includes information about the meeting location, participation eligibility, and where to find related documents such as the notice of meeting, agenda, and proposed resolutions. There is no detailed financial data, management discussion, or voting results included in the text. The document serves as an announcement of the AGM event and related materials rather than the materials themselves or the results of the meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 5912 characters, which is consistent with an announcement rather than a full report.
2026-05-08 French
7_Hyloris Pharmaceuticals BNB 31 12 2025_FR_FV.pdf
Annual Report Classification · 95% confidence The document is titled "COMPTES ANNUELS" which translates to "Annual Accounts" and contains detailed financial statements including balance sheet, income statement, and notes for the fiscal year from 01-01-2025 to 31-12-2025. It also includes identification data, list of directors and auditors, and detailed financial figures for the current and previous fiscal years. The document length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, this is a full Annual Report covering company activity and full financial performance for the year 2025. FY 2025
2026-05-08 French
1.b. Hyloris-CEO_Shareholder_Letter_GM2026_ENFR.pdf
AGM Information Classification · 95% confidence The document is an invitation letter from the CEO of Hyloris Pharmaceuticals SA to shareholders for the Annual Shareholders' Meeting scheduled on June 9, 2026. It includes a summary of the company's 2025 performance, key milestones, and future outlook, but it primarily serves as a convening notice for the AGM. The text mentions that the formal convening notice, agenda, proposed resolutions, and participation formalities are attached or available on the website, indicating this document is the meeting invitation and related information rather than the meeting materials or minutes themselves. The document length is about 7,794 characters, which is consistent with a detailed AGM invitation letter but not a full Annual Report or other financial report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-05-08 French

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.